Clinical Study

The SIAMS-ED Trial: A National, Independent, Multicentre Study on Cardiometabolic and Hormonal Impairment of Men with Erectile Dysfunction Treated with Vardenafil

Table 1

Baseline parameters (604 recruited patients). Data are presented as mean ± standard deviation when normally distributed, median 25th–75th percentiles when skewed, and as percentages when categorical.

Parameter

AgeYears55.3 ± 12.08
Anthropometrics Weight (kg)82.9 ± 13.46
BMI (kg/m2)27.4 ± 4.15
Waist circumference (cm)99.1 ± 11.84
Metabolism Glycaemia (mg/dL)102 [94–114]
HDL cholesterol (mg/dL)45.9 ± 11.03
Triglycerides (mg/dL)139 ±   100–175
Cardiovascular Systolic BP (mmHg)131.41 ± 10.48
Diastolic BP (mmHg)82.17 ± 6.96
Pulse pressure49.25 ± 10.4
Heart rate 75.88 ± 8.17
Hormonal FSH (IU/mL)6.4 ± 10.3
LH (IU/mL)4.86 ± 5.43
Total testosterone (ng/dL)4.04 ± 1.7
Penile CDUPeak systolic velocity (cm/s2)40.4 ± 13.1
Penile resistive index0.83 ± 0.27

Prevalence of diagnostic criteria(%)

CV risk classI (MACE risk < 5%)28.6
II (MACE risk 5–10%)30.2
III (MACE risk 10–15%)21.5
IV (MACE risk 15–20%)12.3
V (MACE risk 20–30%)5.4
VI (MACE risk > 30%)1.9
Metabolic syndrome (yes)≥3 criteria30.8
 Blood pressure≥130/85 or treatment67.0
 Triglycerides≥150 mg/dL (≥1.7 mmol/L)37.5
 HDL cholesterol≤40 mg/dL (≤1.03 mmol/L)33.2
 Fasting glucose≥110 mg/dL (≥6.1 mmol/L)31.7
 Waist≥102 cm23.6
ED severity (IIEF-5 class)Mild (17–21)22.9
Mild to moderate (12–16)37.7
Moderate (8–11)21.5
Severe (<8)17.8